study_no,PMID,title,country,setting,colonisation_site,abx_type,abx_route,resistance_type,bacteria_reported,abx_dur,n_ind_contributedsamples,time_baseline_endoffu,n_ind_outcome,comments,,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,Gut,NA,NA,Aminoglycoside,Gram negatives,0,171,Point prevalence surveys,10,"The use of antibiotics with antianaerobic activity, such as amoxicillin, penicillin, amoxicillin–clavulanic acid, and carbapenems, was discouraged during the SDD period. Surveillance cultures of endotracheal aspirates and oropharyngeal and rectal swabs we",,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,Gut,NA,NA,Fluoroquinolone,Gram negatives,0,171,Point prevalence surveys,10.8,"los = length of stay, will be used to calculate time at risk",,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,Gut,NA,NA,Cephalosporin,Gram negatives,0,171,Point prevalence surveys,12.82,"Because surveillance was done in ICU, los for ICU is taken",,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,Gut,NA,NA,"Aminoglycosides, gentamicin, tobramycin, ciprofloxacin, ceftazidime",Gram negatives,0,171,Point prevalence surveys,7.1,,,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,Gut,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Aminoglycoside,Gram negatives,4,165,Point prevalence surveys,4.1,,,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,Gut,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Fluoroquinolone,Gram negatives,4,165,Point prevalence surveys,4.8,,,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,Gut,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Cephalosporin,Gram negatives,4,165,Point prevalence surveys,4.12,,,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,Gut,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,"Aminoglycosides, gentamicin, tobramycin, ciprofloxacin, ceftazidime",Gram negatives,4,165,Point prevalence surveys,3.4,,,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,Respiratory tract,NA,NA,Aminoglycoside,Gram negatives,0,149,Point prevalence surveys,7.4,,,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,Respiratory tract,NA,NA,Fluoroquinolone,Gram negatives,0,149,Point prevalence surveys,8.2,,,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,Respiratory tract,NA,NA,Cephalosporin,Gram negatives,0,149,Point prevalence surveys,10.2,,,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,Respiratory tract,NA,NA,"Aminoglycosides, gentamicin, tobramycin, ciprofloxacin, ceftazidime",Gram negatives,0,149,Point prevalence surveys,7.1,,,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,Respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Aminoglycoside,Gram negatives,4,149,Point prevalence surveys,12.6,,,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,Respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Fluoroquinolone,Gram negatives,4,149,Point prevalence surveys,1.9,,,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,Respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Cephalosporin,Gram negatives,4,149,Point prevalence surveys,1.6,,,,,,,,
1,19118302,Decontamination of the digestive tract and oropharynx in ICU patients,Netherlands,ICU,Respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,"Aminoglycosides, gentamicin, tobramycin, ciprofloxacin, ceftazidime",Gram negatives,4,149,Point prevalence surveys,1,,,,,,,,
2,18454864,"Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study",France,ICU,Respiratory tract,NA,NA,Ceftazidime or imipenem-resistant,Gram negatives,0,26,36,5,followed up until ICU discharge or 28 days after random assignment if they were discharged from the ICU before,,,,,,,
2,18454864,"Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study",France,ICU,Respiratory tract,NA,NA,Meticillin,Staph aureus,0,26,36,0,Used length of ICU tsays reported in table 6,,,,,,,
2,18454864,"Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study",France,ICU,Respiratory tract,NA,NA,ESBL-producing ,Gram negatives,0,26,36,3,,,,,,,,
2,18454864,"Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study",France,ICU,Respiratory tract,Culture directed,IV,Ceftazidime or imipenem-resistant,Gram negatives,8,18,40,3,,,,,,,,
2,18454864,"Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study",France,ICU,Respiratory tract,Culture directed,IV,Meticillin,Staph aureus,8,18,40,1,,,,,,,,
2,18454864,"Antimicrobial treatment for ventilator-associated tracheobronchitis: a randomized, controlled, multicenter study",France,ICU,Respiratory tract,Culture directed,IV,ESBL-producing ,Gram negatives,8,18,40,2,,,,,,,,
3,11434826,"Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial",Dominican Republic,Outpatient,Respiratory tract,NA,NA,Penicillin,Pneumococcus,0,795,1,210,Baseline,,,,,,,
3,11434826,"Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial",Dominican Republic,Outpatient,Respiratory tract,NA,NA,Amoxicillin,Pneumococcus,0,795,1,3,,,,,,,,
3,11434826,"Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial",Dominican Republic,Outpatient,Respiratory tract,NA,NA,Trimethoprim-sulfamethoxazole,Pneumococcus,0,795,1,157,,,,,,,,
3,11434826,"Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial",Dominican Republic,Outpatient,Respiratory tract,Amoxicillin,Oral,Penicillin,Pneumococcus,5,740,5,151.65,,,,,,,,
3,11434826,"Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial",Dominican Republic,Outpatient,Respiratory tract,Amoxicillin,Oral,Penicillin,Pneumococcus,5,364,10,83.72,,,,,,,,
3,11434826,"Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial",Dominican Republic,Outpatient,Respiratory tract,Amoxicillin,Oral,Penicillin,Pneumococcus,10,358,10,71.6,,,,,,,,
3,11434826,"Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial",Dominican Republic,Outpatient,Respiratory tract,Amoxicillin,Oral,Penicillin,Pneumococcus,5,355,28,85.2,,,,,,,,
3,11434826,"Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial",Dominican Republic,Outpatient,Respiratory tract,Amoxicillin,Oral,Penicillin,Pneumococcus,10,346,28,110.72,,,,,,,,
3,11434826,"Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial",Dominican Republic,Outpatient,Respiratory tract,Amoxicillin,Oral,Trimethoprim-sulfamethoxazole,Pneumococcus,5,355,28,62,,,,,,,,
3,11434826,"Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial",Dominican Republic,Outpatient,Respiratory tract,Amoxicillin,Oral,Trimethoprim-sulfamethoxazole,Pneumococcus,10,346,28,81,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Urine,NA,NA,Amoxicillin,E coli,0,60,1,5,"to receive either a 3-day antibiotic treatment associated with indwelling urethral catheter replacement 4 h after the first administration of antibiotic (i.e. the study group) or no antibiotic, no catheter replacement (i.e. standard of care). Antibiotics ",,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Urine,NA,NA,Amoxicillin,E coli,0,30,7,2,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Urine,Culture directed,Oral or IV,Amoxicillin,E coli,3,30,7,2,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Urine,NA,NA,Amoxicillin,E coli,0,30,15,0,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Urine,Culture directed,Oral or IV,Amoxicillin,E coli,3,30,15,2,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Urine,NA,NA,Amox-clav,Enterobacteriaceae,0,60,1,11,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Urine,NA,NA,Amox-clav,Enterobacteriaceae,0,30,7,1,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Urine,Culture directed,Oral or IV,Amox-clav,Enterobacteriaceae,3,30,7,1,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Urine,NA,NA,Amox-clav,Enterobacteriaceae,0,30,15,1,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Urine,Culture directed,Oral or IV,Amox-clav,Enterobacteriaceae,3,30,15,1,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Urine,NA,NA,Ticacillin,Non fermenters,0,60,1,11,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Urine,NA,NA,Ticacillin,Non fermenters,0,30,7,4,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Urine,Culture directed,Oral or IV,Ticacillin,Non fermenters,3,30,7,2,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Urine,NA,NA,Ticacillin,Non fermenters,0,30,15,2,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Urine,Culture directed,Oral or IV,Ticacillin,Non fermenters,3,30,15,2,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Urine,NA,NA,Cefotaxime,Citrobacter,0,60,1,0,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Urine,NA,NA,Cefotaxime,Citrobacter,0,30,7,0,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Urine,Culture directed,Oral or IV,Cefotaxime,Citrobacter,3,30,7,1,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Urine,NA,NA,Cefotaxime,Citrobacter,0,30,15,0,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Urine,Culture directed,Oral or IV,Cefotaxime,Citrobacter,3,30,15,0,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Urine,NA,NA,Amoxicillin,Enterococcus,0,60,1,8,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Urine,NA,NA,Amoxicillin,Enterococcus,0,30,7,2,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Urine,Culture directed,Oral or IV,Amoxicillin,Enterococcus,3,30,7,1,,,,,,,,
4,17294169,A randomized trial of catheter change and short course of antibiotics for asymptomatic bacteriuria in catheterized ICU patients,France,ICU,Urine,NA,NA,Amoxicillin,Enterococcus,0,30,15,1,,,,,,,,
5,17484870,High-dose oral erythromycin decreased the incidence of parenteral nutrition-associated cholestasis in preterm infants,Hong Kong,Neonatal unit,Gut,NA,NA,Meticillin,Staph aureus,0,75,1,0,"Stool samples for microbiologic culture were collected from the studied infants immediately before treatment, after 10 days of medication, and 4 weeks after the treatment had been terminated.",,,,,,,
5,17484870,High-dose oral erythromycin decreased the incidence of parenteral nutrition-associated cholestasis in preterm infants,Hong Kong,Neonatal unit,Gut,NA,NA,Meticillin,Staph aureus,0,38,10,1,,,,,,,,
5,17484870,High-dose oral erythromycin decreased the incidence of parenteral nutrition-associated cholestasis in preterm infants,Hong Kong,Neonatal unit,Gut,Erythromycin,Oral,Meticillin,Staph aureus,10,37,10,0,,,,,,,,
5,17484870,High-dose oral erythromycin decreased the incidence of parenteral nutrition-associated cholestasis in preterm infants,Hong Kong,Neonatal unit,Gut,NA,NA,Meticillin,Staph aureus,0,38,42,0,,,,,,,,
5,17484870,High-dose oral erythromycin decreased the incidence of parenteral nutrition-associated cholestasis in preterm infants,Hong Kong,Neonatal unit,Gut,Erythromycin,Oral,Meticillin,Staph aureus,14,37,42,0,,,,,,,,
6,15356779,"A prospective, randomized trial of 3 or 14 days of ciprofloxacin treatment for acute urinary tract infection in patients with spinal cord injury",Canada,Outpatient,Urine,Ciprofloxacin,Oral,Fluoroquinolone,Gram negatives,3,30,42,8,"Eight patients (27%) who received treatment for 3 days and 5 patients (17%) who received treatment for 14 days became colonized with a new ciprofloxacin-resistant organism in the urinary tract, on a mucosal surface, or in both locations. These resistant s",,,,,,,
6,15356779,"A prospective, randomized trial of 3 or 14 days of ciprofloxacin treatment for acute urinary tract infection in patients with spinal cord injury",Canada,Outpatient,Urine,Ciprofloxacin,Oral,Fluoroquinolone,Gram negatives,14,30,42,5,But did not specify the groups,,,,,,,
7,28002709,Shortened Antimicrobial Treatment for Acute Otitis Media in Young Children,USA,Outpatient,Respiratory tract,NA,NA,Penicillin,Pneumococcus,0,514,1,85,,,,,,,,
7,28002709,Shortened Antimicrobial Treatment for Acute Otitis Media in Young Children,USA,Outpatient,Respiratory tract,NA,NA,Beta-lactamase producing,H influenzae,0,514,1,55,,,,,,,,
7,28002709,Shortened Antimicrobial Treatment for Acute Otitis Media in Young Children,USA,Outpatient,Respiratory tract,Amox-clav,Oral,Penicillin,Pneumococcus,5,222,14,26,"Only included carriage data at the end-of treatment assessment and not after because did not define when the final visits were for the patients (""typically following year September"")",,,,,,,
7,28002709,Shortened Antimicrobial Treatment for Acute Otitis Media in Young Children,USA,Outpatient,Respiratory tract,Amox-clav,Oral,Beta-lactamase producing,H influenzae,5,222,14,28,,,,,,,,
7,28002709,Shortened Antimicrobial Treatment for Acute Otitis Media in Young Children,USA,Outpatient,Respiratory tract,Amox-clav,Oral,Penicillin,Pneumococcus,10,233,14,23,,,,,,,,
7,28002709,Shortened Antimicrobial Treatment for Acute Otitis Media in Young Children,USA,Outpatient,Respiratory tract,Amox-clav,Oral,Beta-lactamase producing,H influenzae,10,233,14,38,,,,,,,,
8,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,Gut and respiratory tract,NA,NA,Ceftazidime ,Gram negatives,0,868,1,7,,,,,,,,
8,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,Gut and respiratory tract,NA,NA,Ciprofloxacin,Gram negatives,0,868,1,29,,,,,,,,
8,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,Gut and respiratory tract,NA,NA,Imipenem,Gram negatives,0,868,1,2,,,,,,,,
8,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,Gut and respiratory tract,NA,NA,Polymyxin,Gram negatives,0,868,1,0,,,,,,,,
8,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,Gut and respiratory tract,NA,NA,Tobramycin,Gram negatives,0,868,1,47,,,,,,,,
8,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,Gut and respiratory tract,NA,NA,Vancomycin,Enterococcus,0,868,1,10,,,,,,,,
8,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,Gut and respiratory tract,NA,NA,Meticillin,Staph aureus,0,868,1,0,,,,,,,,
8,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,Gut and respiratory tract,NA,NA,Ceftazidime ,Gram negatives,0,395,15.5,21,,,,,,,,
8,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,Gut and respiratory tract,NA,NA,Ciprofloxacin,Gram negatives,0,395,15.5,44,,,,,,,,
8,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,Gut and respiratory tract,NA,NA,Imipenem,Gram negatives,0,395,15.5,26,,,,,,,,
8,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,Gut and respiratory tract,NA,NA,Polymyxin,Gram negatives,0,395,15.5,2,,,,,,,,
8,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,Gut and respiratory tract,NA,NA,Tobramycin,Gram negatives,0,395,15.5,60,,,,,,,,
8,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,Gut and respiratory tract,NA,NA,Vancomycin,Enterococcus,0,395,15.5,5,,,,,,,,
8,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,Gut and respiratory tract,NA,NA,Meticillin,Staph aureus,0,395,15.5,0,,,,,,,,
8,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,Gut and respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Ceftazidime ,Pseudomonas,4,378,13.8,9,,,,,,,,
8,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,Gut and respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Ciprofloxacin,Pseudomonas,4,378,13.8,10,,,,,,,,
8,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,Gut and respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Imipenem,Pseudomonas,4,378,13.8,2,,,,,,,,
8,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,Gut and respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Polymyxin,Pseudomonas,4,378,13.8,4,,,,,,,,
8,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,Gut and respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Tobramycin,Pseudomonas,4,378,13.8,33,,,,,,,,
8,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,Gut and respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Vancomycin,Enterococcus,4,378,13.8,4,,,,,,,,
8,14522530,Effects of selective decontamination of digestive tract on mortality and acquisition of resistant bacteria in intensive care: a randomised controlled trial,Netherlands,ICU,Gut and respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Meticillin,Staph aureus,4,378,13.8,0,,,,,,,,
9,25271544,Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial,Netherlands,ICU,Gut,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,HRMO,Gram negatives,4,1928,Point prevalence surveys,140,There were 384 point-prevalence surveys yielding 3776 rectal swabs,,,,,,,
9,25271544,Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial,Netherlands,ICU,Gut,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,ESBL-producing ,Gram negatives,4,1928,Point prevalence surveys,85,Baseline prevalence not reported,,,,,,,
9,25271544,Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial,Netherlands,ICU,Gut,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Aminoglycoside,Gram negatives,4,1928,Point prevalence surveys,109,,,,,,,,
9,25271544,Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial,Netherlands,ICU,Gut,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Ciprofloxacin,Gram negatives,4,1928,Point prevalence surveys,108,,,,,,,,
9,25271544,Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial,Netherlands,ICU,Gut,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Carbapenem,Gram negatives,4,1928,Point prevalence surveys,30,,,,,,,,
9,25271544,Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial,Netherlands,ICU,Gut,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Colistin,Gram negatives,4,1928,Point prevalence surveys,23,,,,,,,,
9,25271544,Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial,Netherlands,ICU,Gut,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Vancomycin,Enterococcus,4,1928,Point prevalence surveys,11,,,,,,,,
9,25271544,Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial,Netherlands,ICU,Respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,HRMO,Gram negatives,4,1840,Point prevalence surveys,47,HRMO includes carbapenem resistance,,,,,,,
9,25271544,Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial,Netherlands,ICU,Respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,ESBL-producing ,Gram negatives,4,1840,Point prevalence surveys,24,,,,,,,,
9,25271544,Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial,Netherlands,ICU,Respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Aminoglycoside,Gram negatives,4,1840,Point prevalence surveys,50,,,,,,,,
9,25271544,Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial,Netherlands,ICU,Respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Ciprofloxacin,Gram negatives,4,1840,Point prevalence surveys,46,,,,,,,,
9,25271544,Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial,Netherlands,ICU,Respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Carbapenem,Gram negatives,4,1840,Point prevalence surveys,15,,,,,,,,
9,25271544,Effects of Decontamination of the Oropharynx and Intestinal Tract on Antibiotic Resistance in ICUs: A Randomized Clinical Trial,Netherlands,ICU,Respiratory tract,"Combination (cefotaxime, tobramycin, colistin, amphotericin B)",Oral and IV,Colistin,Gram negatives,4,1840,Point prevalence surveys,12,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Gut,NA,NA,HRMO,Enterobacteriaceae,0,1456,Point prevalence surveys,234.416,No length of stay reported in main and supplementary  but same setting as the previous 2 ICU decontamination studies. Assume to be 7 ,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Gut,NA,NA,ESBL-producing ,Gram negatives,0,1456,Point prevalence surveys,230.048,No length of stay reported in main and supplementary  but same setting as the previous 2 ICU decontamination studies. Assume to be 7 ,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Gut,NA,NA,Carbapenem,Gram negatives,0,1456,Point prevalence surveys,46.592,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Gut,NA,NA,Resistance to >3 classes/antibiotics,Gram negatives,0,1456,Point prevalence surveys,157.248,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Gut,NA,NA,Colistin,Gram negatives,0,1456,Point prevalence surveys,7.28,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Gut,NA,NA,HRMO,Non fermenters,0,1456,Point prevalence surveys,46.592,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Gut,NA,NA,Carbapenem,Non fermenters,0,1456,Point prevalence surveys,42.224,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Gut,NA,NA,Colistin,Non fermenters,0,1456,Point prevalence surveys,0,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Gut,NA,NA,Resistance to >3 classes/antibiotics,Non fermenters,0,1456,Point prevalence surveys,34.944,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Gut,NA,NA,Gentamicin,Gram negatives,0,1456,Point prevalence surveys,120.848,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Gut,NA,NA,Vancomycin,Enterococcus,0,1456,Point prevalence surveys,32.032,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Gut,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,HRMO,Enterobacteriaceae,4,1407,Point prevalence surveys,195.573,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Gut,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,ESBL-producing ,Gram negatives,4,1407,Point prevalence surveys,192.759,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Gut,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,Carbapenem,Gram negatives,4,1407,Point prevalence surveys,36.582,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Gut,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,Resistance to >3 classes/antibiotics,Gram negatives,4,1407,Point prevalence surveys,140.7,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Gut,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,Colistin,Gram negatives,4,1407,Point prevalence surveys,18.291,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Gut,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,HRMO,Non fermenters,4,1407,Point prevalence surveys,32.361,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Gut,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,Carbapenem,Non fermenters,4,1407,Point prevalence surveys,25.326,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Gut,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,Colistin,Non fermenters,4,1407,Point prevalence surveys,4.221,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Gut,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,Resistance to >3 classes/antibiotics,Non fermenters,4,1407,Point prevalence surveys,23.919,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Gut,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,Vancomycin,Enterococcus,4,1407,Point prevalence surveys,59.094,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Gut,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,Gentamicin,Gram negatives,4,1407,Point prevalence surveys,101.304,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Respiratory tract,NA,NA,HRMO,Enterobacteriaceae,0,1456,Point prevalence surveys,96.096,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Respiratory tract,NA,NA,ESBL-producing ,Gram negatives,0,1456,Point prevalence surveys,93.184,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Respiratory tract,NA,NA,Carbapenem,Gram negatives,0,1456,Point prevalence surveys,20.384,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Respiratory tract,NA,NA,Resistance to >3 classes/antibiotics,Gram negatives,0,1456,Point prevalence surveys,58.24,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Respiratory tract,NA,NA,Colistin,Gram negatives,0,1456,Point prevalence surveys,1.456,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Respiratory tract,NA,NA,HRMO,Non fermenters,0,1456,Point prevalence surveys,49.504,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Respiratory tract,NA,NA,Carbapenem,Non fermenters,0,1456,Point prevalence surveys,45.136,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Respiratory tract,NA,NA,Colistin,Non fermenters,0,1456,Point prevalence surveys,4.368,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Respiratory tract,NA,NA,Resistance to >3 classes/antibiotics,Non fermenters,0,1456,Point prevalence surveys,36.4,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Respiratory tract,NA,NA,Meticillin,Staph aureus,0,1456,Point prevalence surveys,24.752,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Respiratory tract,NA,NA,Gentamicin,Gram negatives,0,1456,Point prevalence surveys,55.328,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Respiratory tract,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,HRMO,Enterobacteriaceae,4,1407,Point prevalence surveys,66.129,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Respiratory tract,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,ESBL-producing ,Gram negatives,4,1407,Point prevalence surveys,63.315,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Respiratory tract,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,Carbapenem,Gram negatives,4,1407,Point prevalence surveys,7.035,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Respiratory tract,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,Resistance to >3 classes/antibiotics,Gram negatives,4,1407,Point prevalence surveys,49.245,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Respiratory tract,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,Colistin,Gram negatives,4,1407,Point prevalence surveys,4.221,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Respiratory tract,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,HRMO,Non fermenters,4,1407,Point prevalence surveys,37.989,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Respiratory tract,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,Carbapenem,Non fermenters,4,1407,Point prevalence surveys,33.768,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Respiratory tract,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,Colistin,Non fermenters,4,1407,Point prevalence surveys,2.814,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Respiratory tract,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,Resistance to >3 classes/antibiotics,Non fermenters,4,1407,Point prevalence surveys,30.954,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Respiratory tract,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,Meticillin,Staph aureus,4,1407,Point prevalence surveys,23.919,,,,,,,,
10,30347072,Decontamination Strategies and Bloodstream Infections With Antibiotic-Resistant Microorganisms in Ventilated Patients: A Randomized Clinical Trial,Netherlands,ICU,Respiratory tract,"Combination (colistin, tobramycin, and nystatin)",Oral and IV,Gentamicin,Staph aureus,4,1407,Point prevalence surveys,56.28,,,,,,,,
11,16392777,Acute uncomplicated lower urinary tract infections in general practice: Clinical and microbiological cute rates after three- versus five-day treatment with trimethoprim,Netherlands,Outpatient,Urine,NA,NA,Trimethoprim-sulfamethoxazole,E coli,0,128.9583333,1,13,,,,,,,,
11,16392777,Acute uncomplicated lower urinary tract infections in general practice: Clinical and microbiological cute rates after three- versus five-day treatment with trimethoprim,Netherlands,Outpatient,Urine,Trimethoprim-sulfamethoxazole,Oral,Trimethoprim-sulfamethoxazole,E coli,1,127.443609,2,18,,,,,,,,
11,16392777,Acute uncomplicated lower urinary tract infections in general practice: Clinical and microbiological cute rates after three- versus five-day treatment with trimethoprim,Netherlands,Outpatient,Urine,Trimethoprim-sulfamethoxazole,Oral,Trimethoprim-sulfamethoxazole,E coli,3,126.7857143,4,17,,,,,,,,
12,18478129,Preventive antibacterial therapy in acute ischemic stroke: A randomized controlled trial,Germany,Hospital,Gut,NA,NA,Fluoroquinolone,E coli,0,59,1,1,,,,,,,,
12,18478129,Preventive antibacterial therapy in acute ischemic stroke: A randomized controlled trial,Germany,Hospital,Gut,NA,NA,Fluoroquinolone,E coli,0,20,9,1,,,,,,,,
12,18478129,Preventive antibacterial therapy in acute ischemic stroke: A randomized controlled trial,Germany,Hospital,Gut,Moxfloxacin,IV,Fluoroquinolone,E coli,5,20,9,1,,,,,,,,
13,18513453,"Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: A randomized controlled trial",Australia,Outpatient,Respiratory tract,NA,NA,Penicillin,Pneumococcus,0,103,1,32.91,,,,,,,,
13,18513453,"Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: A randomized controlled trial",Australia,Outpatient,Respiratory tract,NA,NA,Beta-lactamase producing,H influenzae,0,103,1,4.14,,,,,,,,
13,18513453,"Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: A randomized controlled trial",Australia,Outpatient,Respiratory tract,NA,NA,Penicillin,Pneumococcus,0,47,168,19,,,,,,,,
13,18513453,"Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: A randomized controlled trial",Australia,Outpatient,Respiratory tract,Amoxicillin,Oral,Beta-lactamase producing,H influenzae,171,50,168,17,,,,,,,,
13,18513453,"Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: A randomized controlled trial",Australia,Outpatient,Respiratory tract,NA,NA,Penicillin,Pneumococcus,0,47,168,1,,,,,,,,
13,18513453,"Compared to placebo, long-term antibiotics resolve otitis media with effusion (OME) and prevent acute otitis media with perforation (AOMwiP) in a high-risk population: A randomized controlled trial",Australia,Outpatient,Respiratory tract,Amoxicillin,Oral,Beta-lactamase producing,H influenzae,171,50,168,6,,,,,,,,
14,18818954,Ceftibuten versus trimethoprim-sulfamethoxazole for oral treatment of febrile urinary tract infection in children,Sweden,Hospital,Urine,NA,NA,Trimethoprim-sulfamethoxazole,Gram negatives,0,128,1,0,,,,,,,,
14,18818954,Ceftibuten versus trimethoprim-sulfamethoxazole for oral treatment of febrile urinary tract infection in children,Sweden,Hospital,Urine,NA,NA,Ceftibuten,Gram negatives,0,255,1,0,,,,,,,,
14,18818954,Ceftibuten versus trimethoprim-sulfamethoxazole for oral treatment of febrile urinary tract infection in children,Sweden,Hospital,Urine,Trimethoprim-sulfamethoxazole,Oral,Trimethoprim-sulfamethoxazole,Gram negatives,10,128,11,4,,,,,,,,
14,18818954,Ceftibuten versus trimethoprim-sulfamethoxazole for oral treatment of febrile urinary tract infection in children,Sweden,Hospital,Urine,Trimethoprim-sulfamethoxazole,Oral,Ceftibuten,Gram negatives,10,255,11,0,,,,,,,,
14,18818954,Ceftibuten versus trimethoprim-sulfamethoxazole for oral treatment of febrile urinary tract infection in children,Sweden,Hospital,Urine,Ceftibuten,Oral,Trimethoprim-sulfamethoxazole,Gram negatives,10,128,11,1,,,,,,,,
14,18818954,Ceftibuten versus trimethoprim-sulfamethoxazole for oral treatment of febrile urinary tract infection in children,Sweden,Hospital,Urine,Ceftibuten,Oral,Ceftibuten,Gram negatives,10,255,11,0,,,,,,,,
15,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Urine,NA,NA,Fosfomycin trometamol,Gram negatives,0,260,1,10,,,,,,,,
15,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Urine,NA,NA,Fosfomycin trometamol,Enterococcus,0,260,1,0,,,,,,,,
15,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Urine,NA,NA,Fosfomycin trometamol,Staph saprophyticus,0,260,1,1,,,,,,,,
15,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Urine,NA,NA,Imipenem,Gram negatives,0,260,1,1,,,,,,,,
15,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Urine,NA,NA,Ceftriaxone,Gram negatives,0,260,1,20,,,,,,,,
15,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Urine,NA,NA,Ciprofloxacin,Gram negatives,0,260,1,54,,,,,,,,
15,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Urine,NA,NA,Ciprofloxacin,Staph saprophyticus,0,260,1,1,,,,,,,,
15,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Urine,NA,NA,Levofloxacin,Gram negatives,0,260,1,34,,,,,,,,
15,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Urine,NA,NA,Levofloxacin,Staph saprophyticus,0,260,1,1,,,,,,,,
15,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Urine,NA,NA,Trimethoprim-sulfamethoxazole,Gram negatives,0,260,1,74,,,,,,,,
15,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Urine,NA,NA,Trimethoprim-sulfamethoxazole,Staph saprophyticus,0,260,1,2,,,,,,,,
15,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Urine,NA,NA,Gentamicin,Gram negatives,0,260,1,57,,,,,,,,
15,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Urine,NA,NA,Gentamicin,Enterococcus,0,260,1,0,,,,,,,,
15,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Urine,NA,NA,Ampicillin,Gram negatives,0,260,1,105,,,,,,,,
15,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Urine,NA,NA,Ampicillin,Enterococcus,0,260,1,1,,,,,,,,
15,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Urine,Fosfomycin trometamol,Oral,Fosfomycin trometamol,Gram negatives,1,130,8,8,,,,,,,,
15,20585969,A randomized comparative study of single-dose fosfomycin and 5-day ciprofloxacin in female patients with uncomplicated lower urinary tract infections,Turkey,Outpatient,Urine,Ciprofloxacin,Oral,Ciprofloxacin,Gram negatives,5,130,8,12,,,,,,,,
16,21269858,Single-dose extended-release azithromycin versus a 10-day regimen of amoxicillin/clavulanate for the treatment of children with acute otitis media,Costa Rica and Dominican Republic,Outpatient,Respiratory tract,NA,NA,Penicillin,Pneumococcus,0,565,1,86,,,,,,,,
16,21269858,Single-dose extended-release azithromycin versus a 10-day regimen of amoxicillin/clavulanate for the treatment of children with acute otitis media,Costa Rica and Dominican Republic,Outpatient,Respiratory tract,NA,NA,Beta-lactamase producing,M catarhalis,0,565,1,58,,,,,,,,
16,21269858,Single-dose extended-release azithromycin versus a 10-day regimen of amoxicillin/clavulanate for the treatment of children with acute otitis media,Costa Rica and Dominican Republic,Outpatient,Respiratory tract,NA,NA,Oxacillin,Staph aureus,0,565,1,2,,,,,,,,
16,21269858,Single-dose extended-release azithromycin versus a 10-day regimen of amoxicillin/clavulanate for the treatment of children with acute otitis media,Costa Rica and Dominican Republic,Outpatient,Respiratory tract,NA,NA,Azithromycin,Pneumococcus,0,282,1,25,,,,,,,,
16,21269858,Single-dose extended-release azithromycin versus a 10-day regimen of amoxicillin/clavulanate for the treatment of children with acute otitis media,Costa Rica and Dominican Republic,Outpatient,Respiratory tract,NA,NA,Amox-clav,H influenzae,0,565,1,1,,,,,,,,
16,21269858,Single-dose extended-release azithromycin versus a 10-day regimen of amoxicillin/clavulanate for the treatment of children with acute otitis media,Costa Rica and Dominican Republic,Outpatient,Respiratory tract,NA,NA,Amox-clav,Pneumococcus,0,283,1,4,,,,,,,,
16,21269858,Single-dose extended-release azithromycin versus a 10-day regimen of amoxicillin/clavulanate for the treatment of children with acute otitis media,Costa Rica and Dominican Republic,Outpatient,Respiratory tract,NA,NA,Penicillin,Pneumococcus,0,93,5,18,,,,,,,,
16,21269858,Single-dose extended-release azithromycin versus a 10-day regimen of amoxicillin/clavulanate for the treatment of children with acute otitis media,Costa Rica and Dominican Republic,Outpatient,Respiratory tract,NA,NA,Beta-lactamase producing,M catarhalis,0,93,5,0,,,,,,,,
16,21269858,Single-dose extended-release azithromycin versus a 10-day regimen of amoxicillin/clavulanate for the treatment of children with acute otitis media,Costa Rica and Dominican Republic,Outpatient,Respiratory tract,NA,NA,Beta-lactamase producing,H influenzae,0,93,5,1,,,,,,,,
16,21269858,Single-dose extended-release azithromycin versus a 10-day regimen of amoxicillin/clavulanate for the treatment of children with acute otitis media,Costa Rica and Dominican Republic,Outpatient,Respiratory tract,NA,NA,Penicillin,Pneumococcus,0,116,5,16,,,,,,,,
16,21269858,Single-dose extended-release azithromycin versus a 10-day regimen of amoxicillin/clavulanate for the treatment of children with acute otitis media,Costa Rica and Dominican Republic,Outpatient,Respiratory tract,NA,NA,Beta-lactamase producing,H influenzae,0,116,5,1,,,,,,,,
17,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Respiratory tract,NA,NA,Tobramycin,Pseudomonas,0,35,1,0,,,,,,,,
17,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,14,17,30,0,,,,,,,,
17,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,30,11,30,0,,,,,,,,
17,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,14,17,60,0,,,,,,,,
17,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,60,11,60,0,,,,,,,,
17,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,14,17,90,0,,,,,,,,
17,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,90,11,90,0,,,,,,,,
17,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,14,17,120,0,,,,,,,,
17,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,104,11,120,0,,,,,,,,
17,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,14,17,150,0,,,,,,,,
17,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,104,11,150,0,,,,,,,,
17,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,14,17,210,0,,,,,,,,
17,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,104,11,210,0,,,,,,,,
17,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,14,17,270,0,,,,,,,,
17,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,104,11,270,0,,,,,,,,
17,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,14,17,360,0,,,,,,,,
17,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,104,11,360,0,,,,,,,,
17,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,14,11,450,0,,,,,,,,
17,26340658,Eradication therapy against pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis,Spain,Outpatient,Respiratory tract,Tobramycin and ceftzidime,IV and inhaled,Tobramycin,Pseudomonas,104,17,450,0,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,NA,NA,Amoxicillin,E coli,0,220,1,100,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,NA,NA,Amoxicillin,E coli,0,68,180,41,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Amoxicillin,E coli,180,68,180,32,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,NA,NA,Amoxicillin,E coli,0,67,365,35,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Amoxicillin,E coli,365,67,365,37,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,NA,NA,Cefalexin,E coli,0,225,1,11,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,NA,NA,Cefalexin,E coli,0,68,180,5,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Cefalexin,E coli,180,67,180,5,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,NA,NA,Cefalexin,E coli,0,67,365,6,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Cefalexin,E coli,365,75,365,5,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,NA,NA,Ciprofloxacin,E coli,0,219,1,5,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,NA,NA,Ciprofloxacin,E coli,0,68,180,5,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Ciprofloxacin,E coli,180,68,180,5,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,NA,NA,Ciprofloxacin,E coli,0,67,365,5,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Ciprofloxacin,E coli,365,67,365,5,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,NA,NA,Trimethoprim-sulfamethoxazole,E coli,0,218,1,58,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,NA,NA,Trimethoprim-sulfamethoxazole,E coli,0,68,180,16,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Trimethoprim-sulfamethoxazole,E coli,180,68,180,18,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,NA,NA,Trimethoprim-sulfamethoxazole,E coli,0,67,365,25,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Trimethoprim-sulfamethoxazole,E coli,365,67,365,17,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,NA,NA,Amox-clav,E coli,0,217,1,14,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,NA,NA,Amox-clav,E coli,0,68,180,7,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Amox-clav,E coli,180,67,180,2,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,NA,NA,Amox-clav,E coli,0,67,365,5,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Amox-clav,E coli,365,75,365,5,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,NA,NA,Mecillinam,E coli,0,215,1,5,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,NA,NA,Mecillinam,E coli,0,68,180,0,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Mecillinam,E coli,180,68,180,1,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,NA,NA,Mecillinam,E coli,0,67,365,2,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Mecillinam,E coli,365,66,365,0,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,NA,NA,Nitrofurantoin,E coli,0,215,1,1,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,NA,NA,Nitrofurantoin,E coli,0,68,180,1,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Nitrofurantoin,E coli,180,68,180,4,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,NA,NA,Nitrofurantoin,E coli,0,67,365,3,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Nitrofurantoin,E coli,365,66,365,2,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,NA,NA,Trimethoprim,E coli,0,215,1,67,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,NA,NA,Trimethoprim,E coli,0,68,180,31,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Trimethoprim,E coli,180,68,180,20,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,NA,NA,Trimethoprim,E coli,0,67,365,31,,,,,,,,
18,29766842,Continuous low-dose antibiotic prophylaxis to prevent urinary tract infection in adults who perform clean intermittent self-catheterisation: The AnTIC RCT,UK,Outpatient,Urine,"Nitrofurantoin, trimethoprim or cefalexin",Oral,Trimethoprim,E coli,365,66,365,20,,,,,,,,
19,31821452,Increased risk of acquisition and transmission of ESBL-producing Enterobacteriaceae in malnourished children exposed to amoxicillin,Nigeria,Outpatient,Gut,NA,NA,ESBL-producing ,Enterobacteriaceae,0,468,1,141,,,,,,,,
19,31821452,Increased risk of acquisition and transmission of ESBL-producing Enterobacteriaceae in malnourished children exposed to amoxicillin,Nigeria,Outpatient,Gut,NA,NA,ESBL-producing ,Enterobacteriaceae,0,161,7,52,,,,,,,,
19,31821452,Increased risk of acquisition and transmission of ESBL-producing Enterobacteriaceae in malnourished children exposed to amoxicillin,Nigeria,Outpatient,Gut,Amoxicillin,Oral,ESBL-producing ,Enterobacteriaceae,7,147,7,79,,,,,,,,
19,31821452,Increased risk of acquisition and transmission of ESBL-producing Enterobacteriaceae in malnourished children exposed to amoxicillin,Nigeria,Outpatient,Gut,NA,NA,ESBL-producing ,Enterobacteriaceae,0,117,28,16,,,,,,,,
19,31821452,Increased risk of acquisition and transmission of ESBL-producing Enterobacteriaceae in malnourished children exposed to amoxicillin,Nigeria,Outpatient,Gut,Amoxicillin,Oral,ESBL-producing ,Enterobacteriaceae,7,96,28,8,,,,,,,,
20,30853250,"Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial",Australia,Outpatient,Gut,NA,NA,ESBL-producing ,Enterobacteriaceae,0,90,1,11,,,,,,,,
20,30853250,"Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial",Australia,Outpatient,Respiratory tract,NA,NA,Meticillin,Staph aureus,0,131,1,0,,,,,,,,
20,30853250,"Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial",Australia,Outpatient,Gut,Flucloxacillin,IV,ESBL-producing ,Enterobacteriaceae,8,33,10,4,,,,,,,,
20,30853250,"Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial",Australia,Outpatient,Respiratory tract,Flucloxacillin,IV,Meticillin,Staph aureus,8,35,10,0,,,,,,,,
20,30853250,"Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial",Australia,Hospital,Gut,Ceftiaxone,IV,ESBL-producing ,Enterobacteriaceae,8,48,10,10,,,,,,,,
20,30853250,"Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial",Australia,Hospital,Respiratory tract,Ceftiaxone,IV,Meticillin,Staph aureus,8,49,10,0,,,,,,,,
20,30853250,"Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial",Australia,Outpatient,Gut,Flucloxacillin,IV,ESBL-producing ,Enterobacteriaceae,8,35,90,7,,,,,,,,
20,30853250,"Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial",Australia,Outpatient,Respiratory tract,Flucloxacillin,IV,Meticillin,Staph aureus,8,34,90,0,,,,,,,,
20,30853250,"Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial",Australia,Hospital,Gut,Ceftiaxone,IV,ESBL-producing ,Enterobacteriaceae,8,44,90,8,,,,,,,,
20,30853250,"Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): a single-centre, open-label, randomised, controlled, non-inferiority trial",Australia,Hospital,Respiratory tract,Ceftiaxone,IV,Meticillin,Staph aureus,8,54,90,1,,,,,,,,
21,32130261,Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): A randomised controlled trial,Europe,ICU,Gut,NA,NA,Carbapenem,Gram negatives,0,195,1,0,,,,,,,,
21,32130261,Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): A randomised controlled trial,Europe,ICU,Gut,Meropenem,IV,Carbapenem,Gram negatives,8,101,28,19,,,,,,,,
21,32130261,Meropenem vs standard of care for treatment of neonatal late onset sepsis (NeoMero1): A randomised controlled trial,Europe,ICU,Gut,Ampicillin+gentamicin or cefotaxime+gentamicin,IV,Carbapenem,Gram negatives,7,94,28,7,,,,,,,,
22,32267724,"Targeted retreatment of incompletely recovered chronic obstructive pulmonary disease exacerbations with ciprofloxacin a double-blind, randomized, placebo-controlled, multicenter, phase III clinical trial",UK,Outpatient,Respiratory tract,NA,NA,Ciprofloxacin,Bacteria,0,47,1,1,,,,,,,,
22,32267724,"Targeted retreatment of incompletely recovered chronic obstructive pulmonary disease exacerbations with ciprofloxacin a double-blind, randomized, placebo-controlled, multicenter, phase III clinical trial",UK,Outpatient,Respiratory tract,NA,NA,Ciprofloxacin,Bacteria,0,17,90,1,,,,,,,,
22,32267724,"Targeted retreatment of incompletely recovered chronic obstructive pulmonary disease exacerbations with ciprofloxacin a double-blind, randomized, placebo-controlled, multicenter, phase III clinical trial",UK,Outpatient,Respiratory tract,Ciprofloxacin,Oral,Ciprofloxacin,Bacteria,7,16,90,0,,,,,,,,
23,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Gut,NA,NA,ESBL-producing ,Enterobacteriaceae,0,78,1,3,,,,,,,,
23,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Gut,NA,NA,Carbapenem,Gram negatives,0,78,1,3,,,,,,,,
23,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Gut,NA,NA,Tobramycin,Gram negatives,0,78,1,26,,,,,,,,
23,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Gut,NA,NA,Colistin,Gram negatives,0,78,1,13,,,,,,,,
23,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Gut,NA,NA,ESBL-producing ,Enterobacteriaceae,0,28,30,1,,,,,,,,
23,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Gut,NA,NA,Carbapenem,Gram negatives,0,28,30,1,,,,,,,,
23,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Gut,NA,NA,Tobramycin,Gram negatives,0,28,30,10,,,,,,,,
23,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Gut,NA,NA,Colistin,Gram negatives,0,28,30,4,,,,,,,,
23,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Gut,Combination (tobramycin and colistin sulphate),Oral,ESBL-producing ,Enterobacteriaceae,3,34,30,1,,,,,,,,
23,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Gut,Combination (tobramycin and colistin sulphate),Oral,Carbapenem,Gram negatives,3,34,30,0,,,,,,,,
23,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Gut,Combination (tobramycin and colistin sulphate),Oral,Tobramycin,Gram negatives,3,34,30,15,,,,,,,,
23,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Gut,Combination (tobramycin and colistin sulphate),Oral,Colistin,Gram negatives,3,34,30,4,,,,,,,,
23,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Gut,NA,NA,ESBL-producing ,Enterobacteriaceae,0,78,1,3,,,,,,,,
23,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Gut,NA,NA,Carbapenem,Gram negatives,0,78,1,3,,,,,,,,
23,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Gut,NA,NA,Tobramycin,Gram negatives,0,78,1,26,,,,,,,,
23,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Gut,NA,NA,Colistin,Gram negatives,0,78,1,13,,,,,,,,
23,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Gut,NA,NA,ESBL-producing ,Enterobacteriaceae,0,28,30,1,,,,,,,,
23,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Gut,NA,NA,Carbapenem,Gram negatives,0,28,30,1,,,,,,,,
23,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Gut,NA,NA,Tobramycin,Gram negatives,0,28,30,10,,,,,,,,
23,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Gut,NA,NA,Colistin,Gram negatives,0,28,30,4,,,,,,,,
23,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Gut,Combination (tobramycin and colistin sulphate),Oral,ESBL-producing ,Enterobacteriaceae,3,34,30,1,,,,,,,,
23,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Gut,Combination (tobramycin and colistin sulphate),Oral,Carbapenem,Gram negatives,3,34,30,0,,,,,,,,
23,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Gut,Combination (tobramycin and colistin sulphate),Oral,Tobramycin,Gram negatives,3,34,30,15,,,,,,,,
23,32539786,Prevention of severe infectious complications after colorectal surgery using oral non-absorbable antimicrobial prophylaxis: Results of a multicenter randomized placebo-controlled clinical trial,Netherlands,Hospital,Gut,Combination (tobramycin and colistin sulphate),Oral,Colistin,Gram negatives,3,34,30,4,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,NA,NA,Ciprofloxacin,Gram negatives,0,207,1,2,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,NA,NA,Ciprofloxacin,Staph aureus,0,207,1,2,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,NA,NA,Ciprofloxacin,Enterococcus,0,207,1,4,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,NA,NA,Gentamicin,Gram negatives,0,207,1,5,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,NA,NA,Gentamicin,Staph aureus,0,207,1,1,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,NA,NA,Gentamicin,Enterococcus,0,207,1,33,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,NA,NA,Polymyxin,Gram negatives,0,207,1,15,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,"Combination (ciprofloxacin, gentamicin and polymyxin)",Oral and IV,Ciprofloxacin,Gram negatives,4,175,1,2,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,"Combination (ciprofloxacin, gentamicin and polymyxin)",Oral and IV,Ciprofloxacin,Staph aureus,4,175,1,3,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,"Combination (ciprofloxacin, gentamicin and polymyxin)",Oral and IV,Ciprofloxacin,Enterococcus,4,175,1,13,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,"Combination (ciprofloxacin, gentamicin and polymyxin)",Oral and IV,Gentamicin,Gram negatives,4,175,1,8,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,"Combination (ciprofloxacin, gentamicin and polymyxin)",Oral and IV,Gentamicin,Staph aureus,4,175,1,6,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,"Combination (ciprofloxacin, gentamicin and polymyxin)",Oral and IV,Gentamicin,Enterococcus,4,175,1,53,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,"Combination (ciprofloxacin, gentamicin and polymyxin)",Oral and IV,Polymyxin,Gram negatives,4,175,1,16,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,"Combination (ciprofloxacin, gentamicin and polymyxin)",Oral and IV,Oxacillin,Staph aureus,4,175,1,2,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,"Combination (ciprofloxacin, gentamicin and polymyxin)",Oral and IV,Polymyxin,Gram negatives,4,144,1,10,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,"Combination (ciprofloxacin, gentamicin and polymyxin)",Oral and IV,Oxacillin,Staph aureus,4,144,1,1,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,NA,NA,Ciprofloxacin,Gram negatives,0,203,1,1,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,NA,NA,Ciprofloxacin,Staph aureus,0,203,1,2,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,NA,NA,Ciprofloxacin,Enterococcus,0,203,1,5,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,NA,NA,Gentamicin,Gram negatives,0,203,1,4,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,NA,NA,Gentamicin,Staph aureus,0,203,1,2,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,NA,NA,Gentamicin,Enterococcus,0,203,1,39,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,NA,NA,Polymyxin,Gram negatives,0,203,1,22,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,NA,NA,Oxacillin,Staph aureus,0,203,1,1,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,NA,NA,Ciprofloxacin,Gram negatives,0,171,28,5,Follow up times not reported,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,NA,NA,Ciprofloxacin,Staph aureus,0,171,28,9,Assume during study = 28 days ,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,NA,NA,Ciprofloxacin,Enterococcus,0,171,28,18,Assume end of study = 56 days,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,NA,NA,Gentamicin,Gram negatives,0,171,28,12,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,NA,NA,Gentamicin,Staph aureus,0,171,28,11,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,NA,NA,Gentamicin,Enterococcus,0,171,28,88,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,NA,NA,Polymyxin,Gram negatives,0,171,28,37,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,NA,NA,Oxacillin,Staph aureus,0,171,28,7,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,NA,NA,Ciprofloxacin,Staph aureus,0,138,56,4,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,NA,NA,Ciprofloxacin,Enterococcus,0,138,56,3,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,NA,NA,Gentamicin,Pseudomonas,0,138,56,3,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,NA,NA,Gentamicin,Staph aureus,0,138,56,4,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,NA,NA,Gentamicin,Enterococcus,0,138,56,30,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,NA,NA,Polymyxin,Gram negatives,0,138,56,12,,,,,,,,
24,12379544,"Influence of combined intravenous and topical antibiotic prophylaxis on the incidence of infections, organ dysfunctions, and mortality in critically ill surgical patients: a prospective, stratified, randomized, double-blind, placebo-controlled clinical tr",Germany,ICU,Gut or respiratory tract,NA,NA,Polymyxin,Staph aureus,0,138,56,1,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,
,,,,,,,,,,,,,,,,,,,,,